29.18
-0.84 (-2.80%)
| Penutupan Terdahulu | 30.02 |
| Buka | 29.73 |
| Jumlah Dagangan | 406,273 |
| Purata Dagangan (3B) | 569,141 |
| Modal Pasaran | 1,438,799,488 |
| Harga / Buku (P/B) | 4.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 16 Nov 2026 |
| EPS Cair (TTM) | -3.76 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 14.34 |
| Aliran Tunai Operasi (OCF TTM) | -119.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.54 M |
| Pulangan Atas Aset (ROA TTM) | -23.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ArriVent BioPharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.33 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 9.74% |
| % Dimiliki oleh Institusi | 85.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| General Catalyst Group Management, Llc | 30 Jun 2026 | 1,494,786 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |